Vetoquinol : Q1 2024 sales: in decline but for temporary reasons
>Q1 2024 earnings: -7.8% - Q1 sales came to € 133.7m i.e. down 7.8% with sales of essentials at € 83.4m (-4%) and sales of complementary products at € 50.3m (-13%).Pets were down 9%, as was livestock by 6%. By region, we see growth in Asia-Pacific sales (+1.8% in reported data) while Europe dropped by -5% (including overstocking) and the Americas were down 14% in reported data.In its announcement, the group also stated (as almost always) that its cash gener...V?toquinol is a global player in the animal health sector, serving both the livestock (cattle and pigs) and pet (dogs and cats) markets. Co. designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas and the Asia Pacific region, as an independent entity. Co. is also active in the therapeutic fields of anti-infectives, pain-inflammation and cardiology-nephrology treatment. As of Dec 31 2013, Co.'s product portfolio included brands such as Aurizon®, Epiphen®, Ipakitine®, Marbocyl®, Propalin®, Tolf?dine®, Tolfine®, Clavaseptin®, and Vetprofen®. Co.'s brands are V?toquinol, Tomlyn, and Evsco in the U.S.A. and Equistro for the horse range.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.